Biotech Business - September 22, 2025
Alvotech receives 3 marketing approvals in Japan
Alvotech has announced that its commercialization partner in Japan, Fuji Pharma, has received marketing approval for three new biosimilars from the Japanese Ministry of Health, Labor and Welfare.
Agreement - September 17, 2025
ALK enters partnership with GenSci
ALK has announced a partnership agreement with China-based Changchun GeneScience Pharmaceutical to develop and commercialize ALK’s house dust mite allergy immunotherapy (AIT) products in Mainland China.
Biotech Business - August 25, 2025
Leqembi launched in the EU – Austria and Germany will mark the first launches
BioArctic's partner Eisai has announced that the launch of Leqembi in the EU started in Austria on August 25, 2025, and will be launched in Germany on September 1, 2025.
Biotech Business - July 30, 2025
Oncopeptides partners with SD Pharma
SD Pharma is a Spanish pharmaceutical broker specializing in oncology and hematology and this partnership will broaden physician reach of Pepaxti across hospital channels throughout Spain, states Oncopeptides.
New Market - July 2, 2025
Camurus’ Oczyesa receives marketing authorization in the EU
Camurus has announced that the European Commission (EC) has granted Oczyesa, octreotide subcutaneous depot, marketing authorization for the maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogs.
Digital health - June 10, 2025
Mavatar establishes US presence
Swedish Mavatar has announced the opening of its first US office and the upcoming commercial launch of its platform Mavatar Discovery.
